{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(3)"],"submitter":["Mistry EA"],"pubmed_abstract":["Background
Prior observational studies indicate that lower systolic blood pressure (SBP) after successful endovascular treatment (EVT) is associated with better functional outcomes in patients with acute ischemic stroke. However, whether targeting SBP to levels below the guideline-recommended target of ≤180 mm Hg is safe and efficacious remains to be determined.Methods
The BEST (Blood Pressure After Endovascular Stroke Therapy)-II trial (NCT04116112) is a pragmatic, phase 2, multisite, prospective, randomized, open-label trial with blinded end-point assessment designed to (1) compare the safety of lower SBP targets with higher SBP targets in successfully EVT-treated patients with stroke and (2) inform the design and estimate the probability of success of a future phase 3 tr"],"journal":["Stroke (Hoboken, N.J.)"],"pagination":["e000249"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12778779"],"repository":["biostudies-literature"],"pubmed_title":["Design of the BEST-II Randomized Clinical Trial."],"pmcid":["PMC12778779"],"pubmed_authors":["Mistry EA","Wanderer JP","Prestigiacomo C","Davis T","Lindsell CJ","Khatri P","Lewis RJ","Albers G","Bernard GR","Yeatts S","Hart K"],"additional_accession":[]},"is_claimable":false,"name":"Design of the BEST-II Randomized Clinical Trial.","description":"Background
Prior observational studies indicate that lower systolic blood pressure (SBP) after successful endovascular treatment (EVT) is associated with better functional outcomes in patients with acute ischemic stroke. However, whether targeting SBP to levels below the guideline-recommended target of ≤180 mm Hg is safe and efficacious remains to be determined.Methods
The BEST (Blood Pressure After Endovascular Stroke Therapy)-II trial (NCT04116112) is a pragmatic, phase 2, multisite, prospective, randomized, open-label trial with blinded end-point assessment designed to (1) compare the safety of lower SBP targets with higher SBP targets in successfully EVT-treated patients with stroke and (2) inform the design and estimate the probability of success of a future phase 3 tr","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-06-13T05:12:41.163Z","creation":"2026-06-13T03:09:11.607Z"},"accession":"S-EPMC12778779","cross_references":{"pubmed":["41583626"],"doi":["10.1161/SVIN.121.000249"]}}